• XNK03 in Urothelial Cancer: Q&A with Dr. Anders Ullén, Karolinska University Hospital

  • XNK Therapeutics receives GMP manufacturing license

  • XNK Therapeutics Enters into Research Agreement with Global Pharma Company


    XNK Therapeutics AB, corporate registration number 556894-6601, was declared into bankruptcy 9 April 2024

XNK Therapeutics

Individualized NK Cell Therapies

XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients.

At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed a proprietary technology platform of broad utility and benefits from its tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. XNK is well positioned to bring transformational autologous NK cell-based therapies and new hope to cancer patients around the world.

CEO Quarterly Statement

I am very pleased to report further progress during the third quarter of 2023. After a phase of rapid expansion, we have now started to work with our company culture based on trust, accountability, and collaboration. We have a strong team in place, gradually moving XNK towards our vision of becoming the global leader in autologous NK-cell based therapies.